Nephrol Dial Transplant. 2014 Dec;29(12):2167-77. doi: 10.1093/ndt/gfu006. Epub 2014 Jan 26.
Although measurement of haemoglobin A1c has become the cornerstone for diagnosing diabetes mellitus in routine clinical practice, the role of this biomarker in reflecting long-term glycaemic control in patients with chronic kidney disease has been questioned.
Consensus review paper based on narrative literature review.
As a different association between glycaemic control and morbidity/mortality might be observed in patients with and without renal insufficiency, the European Renal Best Practice, the official guideline body of the European Renal Association-European Dialysis and Transplant Association, presents the current knowledge and evidence of the use of alternative glycaemic markers (glycated albumin, fructosamine, 1,5-anhydroglucitol and continuous glucose monitoring).
Although reference values of HbA1C might be different in patients with chronic kidney disease, it still remains the cornerstone as follow-up of longer term glycaemic control, as most clinical trials have used it as reference.
尽管血红蛋白 A1c 的测量已成为常规临床实践中诊断糖尿病的基石，但该生物标志物在反映慢性肾脏病患者长期血糖控制方面的作用一直受到质疑。
基于文献综述的共识综述论文。
由于肾功能不全患者和肾功能正常患者的血糖控制与发病率/死亡率之间可能存在不同的关联，因此欧洲肾脏最佳实践（欧洲肾脏协会-欧洲透析和移植协会的官方指导机构）介绍了替代血糖标志物（糖化白蛋白、果糖胺、1,5-脱水葡萄糖醇和连续血糖监测）的使用的当前知识和证据。
尽管慢性肾脏病患者的 HbA1C 参考值可能不同，但由于大多数临床试验都将其用作参考，因此它仍然是长期血糖控制随访的基石。
